Due to the important role of tumor cell–pericyte contact in the progression of GBM, some authors have proposed PCs as therapeutic targets for different approaches, such as tracking tumor progression by radioactively labeling PCs, inhibiting pericyte proliferation, and blocking pericyte–GBM cell interactions via Cdc42 inhibition [112]. This evidence concerns the gene CDC42 and glioblastoma.